New Era for Renal-Protective Therapy in Type 2 Diabetes: Better Renal Outcomes in Patients with Type 2 Diabetes Taking Sodium-Glucose Cotransporter 2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors

Endocrinol Metab (Seoul). 2021 Apr;36(2):339-341. doi: 10.3803/EnM.2021.203. Epub 2021 Apr 27.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / drug therapy
  • Dipeptidyl-Peptidase IV Inhibitors* / adverse effects
  • Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
  • Glucose
  • Humans
  • Sodium

Substances

  • Dipeptidyl-Peptidase IV Inhibitors
  • Sodium
  • Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
  • Glucose